Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGT | O15294 | 9/20 | 0.88 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | POLB | P06746 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16487640 | 0.94 | OGT (0.84) | OGTGAAPOLBMAPTTDP1 | |
| SCHEMBL10131963 | 0.94 | OGT (1.00) | OGTGAAPOLBMAPTTDP1 | |
| SCHEMBL16487949 | 0.91 | OGT (0.80) | OGTGAAPOLBMAPTTDP1 | |
| SCHEMBL16488012 | 0.91 | OGT (0.80) | OGTGAAPOLBMAPTTDP1 | |
| SCHEMBL16487964 | 0.91 | OGT (0.75) | OGTGAAPOLBMAPTTDP1 | |
| SCHEMBL16488014 | 0.90 | OGT (0.72) | OGTGAAPOLBMAPTTDP1 | |
| SCHEMBL16487676 | 0.89 | MEN1 (0.77) | OGTPOLBMAPTTP53SMN1; SMN2 | |
| SCHEMBL16488019 | 0.88 | OGT (0.78) | OGTGAAPOLBMAPTTDP1 | |
| SCHEMBL16487615 | 0.88 | OGT (0.73) | OGTGAAPOLBMAPTTDP1 | |
| SCHEMBL16487594 | 0.88 | OGT (0.75) | OGTGAAPOLBMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-8957075-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957075-B2 | O-GlcNAc transferase inhibitors and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-02-17 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-03 | — | — | US | disclosed |
| WO-2010141074-A2 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20090325944-A1 | Methods and Compositions for Modulating Glycosylation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-31 | — | — | US | disclosed |
| US-20090325944-A1 | Methods and Compositions for Modulating Glycosylation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-31 | — | — | US | disclosed |
| WO-2007120638-A2 | METHODS AND COMPOSITIONS FOR MODULATING GLYCOSYLATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | OGT 3728/4885GAA 2807/4885POLB 352/4885 |
| US-20090325944-A1 | Methods and Compositions for Modulating Glycosylation | IAPP, OGA, IDE | OGT 31/4885GAA 120/4885POLB 4172/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | OGT 3673/4885GAA 411/4885POLB 439/4885 |
| US-20120108605-A1 | O-GLCNAC TRANSFERASE INHIBITORS AND USES THEREOF | OGA, OGT, UGGT1 | OGT 2/4885GAA 51/4885POLB 3030/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | OGT 1605/4885GAA 14/4885POLB 52/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | OGT 610/4885GAA 327/4885POLB 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.